The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is based on a red algae compound that can treat more than 200 different strains of virus.
The Carragelose® polymer forms a physical barrier on the nasal and oral mucosa to prevent viruses from attaching to cells. This can prevent or noticeably reduce the duration of a cold. At the same time, the compound forms a soothing and moisturizing barrier on the nose and throat.
Marinomed obtained certification for another medical device (class Is) in July 2018. This was a new nasal spray to combat the replication of viruses and release blocked airways, using a combination of anti-viral and decongestant properties on a physical basis for the first time.
The company made its debut on the market in 2008 with a medical device in Austria. Carragelose® is now used in six different products: four nasal sprays, a throat spray and lozenges.
A series of additional products is currently in the development stage.
In 2015, Marinomed succeeded in increasing the bioavailability of hardly soluble compounds to treat sensitive tissues such as nose and eyes via the Marinosolv® technology platform. Marinosolv® is currently registered as a patent in all of the company’s internationally important target markets.
In many cases, it is not possible to use solutions such as alcohol on mucous membranes. Nasal sprays – to treat allergic rhinitis, for example – contain undissolved particles of the medicinal product. Marinomed has developed a technology to dissolve these compounds and enhance their bioavailability. This allows the dose to be lowered, while boosting the drug’s efficacy at the same time. The lower dose can also reduce undesirable side effects and costs.
Marinomed is initially using this technology in familiar compounds for well-known applications to treat allergies. However, as Marinosolv® is not limited to specific drugs or indications, it may be used for other applications in future, offering a vast amount of potential.
Clinical trials for the first product from this technology platform were prepared in 2017. As a result, Marinomed estimates it will be able to start the clinical approval study (Phase III) earlier than expected in autumn 2018.
An ophthalmic product is also in the process of development.